Ultimately, targeting YTHDF2 could serve as a promising approach to improve treatment outcomes and survival rates for patients with liver cancer, offering a more effective means of overcoming immune suppression and enhancing immune cell-mediated tumor clearance. Here, YTHDF2 is linked to liver cancer.